X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (5) 5
clinical activity (4) 4
index medicus (4) 4
lung cancer, non-small cell (4) 4
nivolumab (4) 4
antibody mpdl3280a (3) 3
atezolizumab (3) 3
immunotherapy (3) 3
ligand (3) 3
metastasis (3) 3
pd-l1 (3) 3
abridged index medicus (2) 2
adult (2) 2
aged (2) 2
aged, 80 and over (2) 2
analysis (2) 2
antibody (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
cancer immunotherapy (2) 2
carcinoma, non-small-cell lung - drug therapy (2) 2
carcinoma, non-small-cell lung - mortality (2) 2
care and treatment (2) 2
chemotherapy (2) 2
clinical trials (2) 2
disease-free survival (2) 2
docetaxel (2) 2
female (2) 2
humans (2) 2
internal medicine (2) 2
ligands (2) 2
lung cancer (2) 2
lung neoplasms - drug therapy (2) 2
lung neoplasms - mortality (2) 2
male (2) 2
medical colleges (2) 2
medicine, general & internal (2) 2
middle aged (2) 2
mpdl3280a (2) 2
multicenter (2) 2
open-label (2) 2
programmed death-1 (2) 2
research (2) 2
respiratory system (2) 2
safety (2) 2
treatment outcome (2) 2
trial (2) 2
2nd (1) 1
anatomy & morphology (1) 1
anti-pd-l1 (1) 1
antibodies (1) 1
antibodies - therapeutic use (1) 1
antibodies, monoclonal - administration & dosage (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic agents - therapeutic use (1) 1
anti–pd-l1 (1) 1
b7-h1 antigen - metabolism (1) 1
biomarkers (1) 1
blockade (1) 1
cancer (1) 1
cell lung-cancer (1) 1
cells (1) 1
checkpoint inhibitor (1) 1
diagnostic assay (1) 1
drug administration schedule (1) 1
drug therapy (1) 1
europe - epidemiology (1) 1
health maintenance organizations (1) 1
histology (1) 1
iii trial (1) 1
immune (1) 1
immune checkpoint inhibitor (1) 1
immunoglobulins (1) 1
immunohistochemistry (1) 1
in-vivo (1) 1
infusions, intravenous (1) 1
kaplan-meier estimate (1) 1
medical laboratory technology (1) 1
methods (1) 1
monoclonal antibodies (1) 1
mpdl3280a anti-pdl1 (1) 1
non-small cell lung cancer (1) 1
non-small-cell lung cancer (1) 1
non–small cell lung cancer (1) 1
north america - epidemiology (1) 1
nsclc (1) 1
oncology, experimental (1) 1
pathology (1) 1
pathway (1) 1
patients (1) 1
pembrolizumab (1) 1
pharmaceuticals (1) 1
phase (1) 1
product development (1) 1
prognosis (1) 1
research articles (1) 1
research institutes (1) 1
responses (1) 1
safety and security measures (1) 1
solid tumors (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2016, Volume 389, Issue 10066, pp. 255 - 265
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10030, pp. 1837 - 1846
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 11/2018, Volume 13, Issue 11, pp. 1733 - 1742
The FIR phase II study ( ) evaluated the efficacy and safety of anti–programmed death-ligand 1 (PD-L1) atezolizumab in advanced NSCLC selected by tumor cell... 
NSCLC | Immunotherapy | Anti–PD-L1 | SOLID TUMORS | PROGRAMMED DEATH-1 | Anti-PD-L1 | ANTIBODY MPDL3280A | DOCETAXEL | CHEMOTHERAPY | CELL LUNG-CANCER | TRIAL | IMMUNE | PEMBROLIZUMAB | ONCOLOGY | RESPIRATORY SYSTEM | CLINICAL ACTIVITY
Journal Article
Applied Immunohistochemistry and Molecular Morphology, ISSN 1541-2016, 02/2019, Volume 27, Issue 2, pp. 92 - 100
Cancer immunotherapies, such as atezolizumab, are proving to be a valuable therapeutic strategy across indications, including non-small cell lung cancer... 
PD-L1 | atezolizumab | immunohistochemistry | SP142 | diagnostic assay | cancer immunotherapy | CELLS | SAFETY | ANATOMY & MORPHOLOGY | ANTIBODY | PATHOLOGY | MPDL3280A | PHASE | LIGAND | MEDICAL LABORATORY TECHNOLOGY | CLINICAL ACTIVITY | Immunohistochemistry | Usage | Prognosis | Research | Lung cancer, Non-small cell | Drug therapy | Methods | Urinary tract cancer
Journal Article
European Journal of Cancer, ISSN 0959-8049, 09/2018, Volume 101, pp. 201 - 209
Atezolizumab, an anti-programmed death-ligand 1 (PD-L1) antibody, inhibits PD-L1:PD-1 and PD-L1:B7.1 interactions, restoring anticancer immunity. Here, we... 
Non-small-cell lung cancer | PD-L1 | Immune checkpoint inhibitor | Atezolizumab | MULTICENTER | ANTIBODY | OPEN-LABEL | DOCETAXEL | MPDL3280A | TRIAL | ONCOLOGY | LIGAND | NIVOLUMAB | BLOCKADE | Safety and security measures | Metastasis | Research | Lung cancer, Non-small cell | Oncology, Experimental | Cancer
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.